Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback